PT3359528T - Agonistas de ppar, compostos, composições farmacêuticas e métodos de utilização dos mesmos - Google Patents

Agonistas de ppar, compostos, composições farmacêuticas e métodos de utilização dos mesmos

Info

Publication number
PT3359528T
PT3359528T PT167856111T PT16785611T PT3359528T PT 3359528 T PT3359528 T PT 3359528T PT 167856111 T PT167856111 T PT 167856111T PT 16785611 T PT16785611 T PT 16785611T PT 3359528 T PT3359528 T PT 3359528T
Authority
PT
Portugal
Prior art keywords
compounds
methods
pharmaceutical compositions
ppar agonists
ppar
Prior art date
Application number
PT167856111T
Other languages
English (en)
Original Assignee
Salk Inst Biological Studies
Mitobridge Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57200096&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3359528(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Salk Inst Biological Studies, Mitobridge Inc filed Critical Salk Inst Biological Studies
Publication of PT3359528T publication Critical patent/PT3359528T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PT167856111T 2015-10-07 2016-10-05 Agonistas de ppar, compostos, composições farmacêuticas e métodos de utilização dos mesmos PT3359528T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562238629P 2015-10-07 2015-10-07
US201562243263P 2015-10-19 2015-10-19
US201662352348P 2016-06-20 2016-06-20

Publications (1)

Publication Number Publication Date
PT3359528T true PT3359528T (pt) 2022-04-07

Family

ID=57200096

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167856111T PT3359528T (pt) 2015-10-07 2016-10-05 Agonistas de ppar, compostos, composições farmacêuticas e métodos de utilização dos mesmos

Country Status (25)

Country Link
US (5) US10399958B2 (pt)
EP (3) EP3359528B1 (pt)
JP (2) JP6657413B2 (pt)
CN (3) CN113004205A (pt)
AU (3) AU2016333963C1 (pt)
BR (1) BR112018006866B1 (pt)
CA (1) CA3000431A1 (pt)
CO (1) CO2018004473A2 (pt)
DK (1) DK3359528T3 (pt)
EA (1) EA037371B1 (pt)
ES (2) ES2906379T3 (pt)
HK (1) HK1257907A1 (pt)
HU (1) HUE058154T2 (pt)
IL (3) IL258225B (pt)
JO (3) JO3738B1 (pt)
MA (2) MA52648A (pt)
MX (2) MX2020011100A (pt)
PH (1) PH12018500762A1 (pt)
PL (1) PL3359528T3 (pt)
PT (1) PT3359528T (pt)
SG (1) SG10201906400SA (pt)
TW (3) TWI730408B (pt)
UA (1) UA122237C2 (pt)
WO (1) WO2017062468A1 (pt)
ZA (4) ZA201802029B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3359528T (pt) 2015-10-07 2022-04-07 Salk Inst Biological Studies Agonistas de ppar, compostos, composições farmacêuticas e métodos de utilização dos mesmos
KR102430906B1 (ko) 2016-04-13 2022-08-10 미토브리지, 인크. Ppar 효능제, 화합물, 제약 조성물, 및 그의 사용 방법
MX2019003949A (es) * 2016-10-05 2019-06-10 Mitobridge Inc Metodos para tratar lesion renal aguda.
LT3523283T (lt) * 2016-10-05 2021-07-12 Mitobridge, Inc. Ppar agonistų junginių kristalinės ir druskos formos
US20220331267A1 (en) * 2019-09-05 2022-10-20 Rush University Medical Center Methods and compositions for treatment of demyelinating disorders
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
AU2022286415A1 (en) 2021-06-02 2023-12-14 Astellas Pharma Inc. Methods of use of ppar agonist compounds and pharmaceutical compositions thereof
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228281A (en) 1977-09-23 1980-10-14 Ciba-Geigy Corporation Dicarboxylic acids containing triazine rings
DE4123341A1 (de) 1991-07-15 1993-01-21 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9511694D0 (en) 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
KR20020006626A (ko) 1999-02-26 2002-01-23 폴락 돈나 엘. 신규한 술폰아미드 화합물 및 그의 용도
GB9919413D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
SI1311488T1 (sl) 2000-08-17 2010-01-29 Pfizer Ltd Substituirani imidazoli kot inhibitorji TAFIA
NZ538031A (en) 2002-08-29 2007-10-26 Merck & Co Inc Indoles having anti-diabetic activity
AU2003241836A1 (en) 2002-10-03 2004-04-23 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonists
WO2004060367A1 (en) 2002-12-30 2004-07-22 Fujisawa Pharmaceutical Co., Ltd. Imidazole and triazole derivatives useful as selective cox-1 inhibitors
KR20070087197A (ko) 2003-09-26 2007-08-27 니뽄 다바코 산교 가부시키가이샤 잔여 리포프로테인 생산 저해 방법
RU2007112688A (ru) 2004-09-06 2008-10-20 Ф.Хоффманн-Ля Рош Аг (Ch) Производные 4-аминометилбензамина и их применение в качестве ингибиторов фактора viia
AU2006289470A1 (en) 2005-02-15 2007-03-15 F. Hoffmann-La Roche Ag Amide derivatives as PPAR activators
WO2007030567A2 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. Pparactive compounds
AU2007211319B9 (en) 2006-01-30 2012-05-31 Vtv Therapeutics Llc Substituted imidazole derivatives and their use as PTPase inhibitors
MX2008012404A (es) 2006-03-28 2008-10-09 Novartis Ag Derivados de amida y su aplicacion para el tratamiento de enfermedades relacionadas con proteina-g.
EP2014652B1 (en) 2006-04-18 2014-08-06 Nippon Chemiphar Co., Ltd. Activating agent for peroxisome proliferator activated receptor
DE102006023336A1 (de) 2006-05-18 2007-11-22 Merck Patent Gmbh 1,5-Diphenyl-pyrazole II
CN101085772A (zh) * 2006-06-07 2007-12-12 上海艾力斯医药科技有限公司 一类具有PPARγ激动剂活性的化合物及其应用
EP2128138A1 (en) 2007-01-29 2009-12-02 Takeda Pharmaceutical Company Limited Pyrazole compound
KR20080082541A (ko) 2007-03-07 2008-09-11 동아제약주식회사 퍼옥시좀 증식자-활성화 감마 수용체를 조절하는 신규한페닐프로판산 유도체의 제조방법 및 약학적 용도
JP2008285452A (ja) 2007-05-21 2008-11-27 Ono Pharmaceut Co Ltd PPARα/γデュアルアゴニストおよび糖尿病治療薬を組み合わせてなる医薬
CA2710764A1 (en) 2007-12-28 2009-07-09 The Salk Institute For Biological Studies Methods for enhancing muscle performance and tone
ES2607482T3 (es) 2012-08-28 2017-03-31 Koc Universitesi Placa ósea
WO2014165827A1 (en) * 2013-04-05 2014-10-09 Salk Institute For Biological Studies Ppar agonists
CA2923422C (en) 2013-09-09 2021-09-07 Vtv Therapeutics Llc Use of a ppar-delta agonist for treating muscle atrophy
WO2016057658A1 (en) * 2014-10-08 2016-04-14 Mitobridge, Inc. Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
WO2016057322A1 (en) 2014-10-08 2016-04-14 Salk Institute For Biological Studies Ppar agonists and methods of use thereof
PT3359528T (pt) 2015-10-07 2022-04-07 Salk Inst Biological Studies Agonistas de ppar, compostos, composições farmacêuticas e métodos de utilização dos mesmos
KR102430906B1 (ko) 2016-04-13 2022-08-10 미토브리지, 인크. Ppar 효능제, 화합물, 제약 조성물, 및 그의 사용 방법
LT3523283T (lt) * 2016-10-05 2021-07-12 Mitobridge, Inc. Ppar agonistų junginių kristalinės ir druskos formos
MX2019003949A (es) 2016-10-05 2019-06-10 Mitobridge Inc Metodos para tratar lesion renal aguda.

Also Published As

Publication number Publication date
EP3795566B1 (en) 2023-04-19
MA52098A (fr) 2021-01-27
JP6657413B2 (ja) 2020-03-04
SG10201906400SA (en) 2019-08-27
EA037371B1 (ru) 2021-03-19
TW201722919A (zh) 2017-07-01
TW202012375A (zh) 2020-04-01
ZA201802029B (en) 2022-01-26
EP3359528A1 (en) 2018-08-15
ZA202003662B (en) 2022-08-31
AU2019283837A1 (en) 2020-01-16
US10906885B2 (en) 2021-02-02
WO2017062468A8 (en) 2017-05-11
CA3000431A1 (en) 2017-04-13
US20190337920A1 (en) 2019-11-07
CO2018004473A2 (es) 2018-09-20
IL275392B (en) 2022-05-01
CN113024467A (zh) 2021-06-25
EP3795566A1 (en) 2021-03-24
US20200157074A1 (en) 2020-05-21
BR112018006866B1 (pt) 2023-11-21
MX2020011100A (es) 2022-05-23
AU2020281069A1 (en) 2021-01-07
MA52648A (fr) 2021-10-13
IL275387B (en) 2021-08-31
EP3770146A1 (en) 2021-01-27
BR112018006866A2 (pt) 2018-10-16
ES2949852T3 (es) 2023-10-03
KR20180095797A (ko) 2018-08-28
IL258225B (en) 2021-08-31
CN108349904A (zh) 2018-07-31
HUE058154T2 (hu) 2022-07-28
EP3359528B1 (en) 2022-01-12
TWI742479B (zh) 2021-10-11
US20210253549A1 (en) 2021-08-19
DK3359528T3 (en) 2022-03-07
JOP20200231A1 (ar) 2022-10-30
IL275392A (en) 2020-07-30
US10479775B1 (en) 2019-11-19
PH12018500762A1 (en) 2018-10-29
CN113004205A (zh) 2021-06-22
US20230373948A1 (en) 2023-11-23
AU2016333963B2 (en) 2021-01-07
EA201890776A1 (ru) 2018-09-28
US11578052B2 (en) 2023-02-14
AU2016333963A1 (en) 2018-04-12
ES2906379T3 (es) 2022-04-18
JO3738B1 (ar) 2021-01-31
IL258225A (en) 2018-05-31
JP6866514B2 (ja) 2021-04-28
ZA202003664B (en) 2022-08-31
AU2019283837B2 (en) 2020-12-24
TW201943705A (zh) 2019-11-16
ZA202003663B (en) 2022-08-31
JP2018534355A (ja) 2018-11-22
JOP20200230A1 (ar) 2022-10-30
CN108349904B (zh) 2021-08-31
TWI730408B (zh) 2021-06-11
UA122237C2 (uk) 2020-10-12
PL3359528T3 (pl) 2022-05-30
AU2020281069B2 (en) 2022-10-27
HK1257907A1 (zh) 2019-11-01
AU2016333963C1 (en) 2021-05-27
KR20210126150A (ko) 2021-10-19
MX2020011099A (es) 2022-05-23
JP2020075939A (ja) 2020-05-21
TWI730006B (zh) 2021-06-11
WO2017062468A1 (en) 2017-04-13
IL275387A (en) 2020-07-30
US20190084958A1 (en) 2019-03-21
US10399958B2 (en) 2019-09-03

Similar Documents

Publication Publication Date Title
ZA202003664B (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
HK1243999A1 (zh) 新型3-吲哚取代的衍生物、藥物組合物及使用方法
IL247062A0 (en) Heterocyclic compounds, their preparation and pharmaceutical preparations containing them
EP3139920A4 (en) Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
HUE056172T2 (hu) Szelenoorganikus vegyületeket tartalmazó készítmények és eljárások alkalmazásukra
HK1259372A1 (zh) 治療化合物、其組合物及使用方法
EP3297640A4 (en) Pharmaceutical co-crystal composition and use thereof
HK1243354B (zh) 新穎碘伏組合物及其使用方法
HK1256674A1 (zh) 氘修飾的brigatinib衍生物、含有該化合物的藥物組合物及其用途
IL280690A (en) Pharmaceutical preparations that include DGLA and their use
EP3285758A4 (en) Co-crystal composition and its pharmaceutical use
RO130539B8 (ro) Compoziţie erbicidă, procedeu de preparare şi utilizarea acesteia
HK1258765A1 (zh) 治療性化合物、組合物和它們的使用方法
EP3151826A4 (en) Omega-3 compositions, dosage forms, and methods of use
EP3175851A4 (en) Use of butenylphthalide, usage method thereof and method for preparing same into pharmaceutical composition
HK1254738A1 (zh) 用於進行最小量潤滑的組合物及其用途
IL248578A0 (en) Quinzoline derivatives, pharmaceutical compounds containing them and their uses
IL247645A0 (en) Preparations of seleno-organic compounds and methods of using them
GB201408233D0 (en) Use of polyanionic composition
GB201720445D0 (en) Use of TRPV1 agonists
GB201620933D0 (en) Use of TRPV1 agonists
PL3061765T3 (pl) Pochodna protoescygeniny, sposób jej otrzymywania, zastosowanie i użycie w kompozycjach farmaceutycznych zawierających ten związek
GB201415969D0 (en) Pharmaceutical compositions comprising of hetero-bicyclic derivatives, and methods of use thereof
TH149389B (th) องค์ประกอบสารเคลือบใส กระบวนการสำหรับการเตรียมและการใช้